JP2023541669A - アルツハイマー病の処置のためのβ－アミロイドワクチン - Google Patents

アルツハイマー病の処置のためのβ－アミロイドワクチン Download PDF

Info

Publication number
JP2023541669A
JP2023541669A JP2023517697A JP2023517697A JP2023541669A JP 2023541669 A JP2023541669 A JP 2023541669A JP 2023517697 A JP2023517697 A JP 2023517697A JP 2023517697 A JP2023517697 A JP 2023517697A JP 2023541669 A JP2023541669 A JP 2023541669A
Authority
JP
Japan
Prior art keywords
peptide
seq
residues
linker
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541669A5 (https=
Inventor
ロビン バーバー，
ジーン キニー，
ワーグナー ザーゴ，
Original Assignee
オター プロシーナ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オター プロシーナ リミテッド filed Critical オター プロシーナ リミテッド
Publication of JP2023541669A publication Critical patent/JP2023541669A/ja
Publication of JP2023541669A5 publication Critical patent/JP2023541669A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023517697A 2020-09-17 2021-05-19 アルツハイマー病の処置のためのβ－アミロイドワクチン Pending JP2023541669A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079806P 2020-09-17 2020-09-17
US63/079,806 2020-09-17
PCT/US2021/033180 WO2022060424A1 (en) 2020-09-17 2021-05-19 β-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Publications (2)

Publication Number Publication Date
JP2023541669A true JP2023541669A (ja) 2023-10-03
JP2023541669A5 JP2023541669A5 (https=) 2024-05-28

Family

ID=80776325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517697A Pending JP2023541669A (ja) 2020-09-17 2021-05-19 アルツハイマー病の処置のためのβ－アミロイドワクチン

Country Status (12)

Country Link
US (1) US20230364210A1 (https=)
EP (1) EP4213942A4 (https=)
JP (1) JP2023541669A (https=)
KR (1) KR20230087495A (https=)
CN (1) CN116724046A (https=)
AR (1) AR122127A1 (https=)
AU (1) AU2021345451A1 (https=)
CA (1) CA3192383A1 (https=)
IL (1) IL301223A (https=)
MX (1) MX2023003009A (https=)
TW (1) TW202212348A (https=)
WO (1) WO2022060424A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
EP4661891A2 (en) * 2023-02-06 2025-12-17 Creative Bio-Peptides Inc. Peptides for treating neurological disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531509A (ja) * 2002-02-28 2005-10-20 マインドセット・バイオファーマスーティカルズ・ユーエスエイ・インコーポレイテッド アミロイドβペプチドに対する特異性抗体、医薬組成物、及びその使用方法
WO2013020723A1 (en) * 2011-08-05 2013-02-14 Glaxosmithkline Biologicals S.A. Compositions and uses thereof for the treatment or prevention of alzheimer's disease
JP2019531704A (ja) * 2016-07-29 2019-11-07 ジュノー セラピューティクス インコーポレイテッド 免疫調節ポリペプチドならびに関連する組成物および方法
JP2023526500A (ja) * 2020-05-19 2023-06-21 オター プロシーナ リミテッド アルツハイマー病の処置のためのマルチエピトープワクチン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840838A (en) * 1996-02-29 1998-11-24 University Of Kentucky Research Foundation Process for enhancing the activity of amyloid β peptides
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531509A (ja) * 2002-02-28 2005-10-20 マインドセット・バイオファーマスーティカルズ・ユーエスエイ・インコーポレイテッド アミロイドβペプチドに対する特異性抗体、医薬組成物、及びその使用方法
WO2013020723A1 (en) * 2011-08-05 2013-02-14 Glaxosmithkline Biologicals S.A. Compositions and uses thereof for the treatment or prevention of alzheimer's disease
JP2019531704A (ja) * 2016-07-29 2019-11-07 ジュノー セラピューティクス インコーポレイテッド 免疫調節ポリペプチドならびに関連する組成物および方法
JP2023526500A (ja) * 2020-05-19 2023-06-21 オター プロシーナ リミテッド アルツハイマー病の処置のためのマルチエピトープワクチン

Also Published As

Publication number Publication date
AU2021345451A1 (en) 2023-04-13
US20230364210A1 (en) 2023-11-16
IL301223A (en) 2023-05-01
EP4213942A4 (en) 2025-01-08
TW202212348A (zh) 2022-04-01
MX2023003009A (es) 2023-04-10
EP4213942A1 (en) 2023-07-26
WO2022060424A1 (en) 2022-03-24
KR20230087495A (ko) 2023-06-16
CN116724046A (zh) 2023-09-08
AR122127A1 (es) 2022-08-17
CA3192383A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
US11965005B2 (en) Multi-epitope vaccine for the treatment of Alzheimer's disease
JP2023541669A (ja) アルツハイマー病の処置のためのβ－アミロイドワクチン
JP2023541670A (ja) アルツハイマー病の処置のためのマルチエピトープワクチン
US20250186567A1 (en) Multiepitope vaccine for the treatment of alzheimer's disease
US20230302127A1 (en) Tau vaccine for the treatment of alzheimer's disease
JP2023541671A (ja) シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260428